Vaccination against *Clostridium difficile* using toxin fragments

Janice Spencer, Rosanna Leuzzi, Anthony Buckley, June Irvine, Denise Candlish, Maria Scarselli & Gillian R Douce

To cite this article: Janice Spencer, Rosanna Leuzzi, Anthony Buckley, June Irvine, Denise Candlish, Maria Scarselli & Gillian R Douce (2014) Vaccination against *Clostridium difficile* using toxin fragments, Gut Microbes, 5:2, 225-232, DOI: 10.4161/gmic.27712

To link to this article: https://doi.org/10.4161/gmic.27712
**Vaccination against *Clostridium difficile* using toxin fragments**

Observations and analysis in animal models

Janice Spencer1, Rosanna Leuzzi2, Anthony Buckley1, June Irvine1, Denise Candlish1, Maria Scarselli2, and Gillian R Douce1,*

1Institute of Infection, Immunity, and Inflammation; College of Medicine, Veterinary and Life Sciences; University of Glasgow; Glasgow, UK; 2Novartis Vaccines and Diagnostics; Siena, Italy

Keywords: *Clostridium difficile*, vaccination, toxin fragments, neutralizing antibodies, hamster models, diarrhea, colonization factors, glucosyltransferase activity, protection

*Correspondence to: Gillian R Douce; Email: Gillian.Douce@glasgow.ac.uk

Submitted: 09/20/2013
Revised: 12/08/2013
Accepted: 01/02/2014
Published Online: 01/22/2014
http://dx.doi.org/10.4161/gmic.27712

Addendum to: Leuzzi R, Spencer J, Buckley A, Bretton C, Martineu M, Tulli L, Marchi S, Luzzi E, Irvine J, Candlish D, et al. Protective efficacy induced by recombinant *Clostridium difficile* toxin fragments. Infect Immun 2013; 81:2851-60; PMID:23716610; http://dx.doi.org/10.1128/IAI.01341-12

---

**Clostridium difficile** is a major cause of antibiotic associated diarrhea. Recently, we have shown that effective protection can be mediated in hamsters through the inclusion of specific recombinant fragments from toxin A and B in a systemically delivered vaccine. Interestingly while neutralizing antibodies to the binding domains of both toxin A and B are moderately protective, enhanced survival is observed when fragments from the glucosyltransferase region of toxin B replace those from the binding domain of this toxin. In this addendum, we discuss additional information that has been derived from such vaccination studies. This includes observations on efficacy and cross-protection against different ribotypes mediated by these vaccines and the challenges that remain for a vaccine which prevents clinical symptoms but not colonization. The use and value of vaccination both in the prevention of infection and for treatment of disease relapse will be discussed.

**Introduction**

*Clostridium difficile* is a leading cause of antibiotic associated diarrhea and susceptibility to this infection increases with age, immunodeficiency, and antibiotic treatment. While carriage of the organism within the gut can be asymptomatic, modification of the flora through antibiotic use frequently initiates disease. Symptoms ranging from mild to severe diarrhea are largely associated with the production of two large glucosyltransferase exotoxins, TcdA and TcdB, which modify and damage the cellular architecture of the epithelial surface of the colon. This damage not only limits absorption of water but also induces through inflammasome activation a prolific inflammatory response including an influx of high numbers of polymorphonucleocytes (PMNs). While symptoms can be alleviated through the destruction and removal of the toxin-producing bacteria through treatment with metronidazole or vancomycin, further complications including pseudomembranous colitis, toxic megacolon, and sepsis also occur in a small number of cases.

**Animal Models**

The efficacy of any new treatment for *C. difficile* requires early evaluation in appropriate animal models. Until recently, the “gold standard” model for *C. difficile* infection was considered to be the Syrian Golden hamster. Unlike mice, the challenge of clindamycin treated animals with spores or vegetative cells results in an acute and fatal outcome with many symptoms including diarrhea and inflammation of the colon (including damage resembling pseudomembranous eruptions) similar to those observed in man. In contrast, genetically normal mice only appear to be transiently colonized when experimentally infected, with little...
Vaccination to Prevent *C. difficile*

While current treatments for symptomatic disease are based upon the administration of additional antibiotics, frequent recurrence of disease following withdrawal of treatment has strengthened the need for alternative approaches. Vaccination using toxins or recombinant fragments has been tested in both animals and man with varying and limited success. Protection appears dependent on the production of high levels of neutralizing antibody to both toxin A and toxin B. In fact, passive transfer of monoclonal antibodies to these toxins provides protection against *C. difficile* in human subjects. In man, the presence of high levels of systemic toxin A antibodies alone appears to correlate with protection from *Clostridium difficile* associated diarrhea (CDAD) 8. In contrast, there is some evidence that the level of neutralizing antibodies to toxin B correlates with the prevention of disease and relapse 10-16. While protection has largely been attributed to neutralizing antibodies generated to the binding domains of these toxins, recent work by this group and confirmed by others 19 has indicated that high titers of neutralizing antibodies to toxin B can be generated using regions other than the binding domain. These antibodies appear to provide greater protection in animal models as well as reducing the longevity and severity of diarrheal symptoms associated with this disease.

Protective Efficacy of Toxin Repetitive Binding Domains (RBD)

Early studies in animals and more recent clinical studies in man have focused on the use of denatured versions of the proteins to generate protective immunity 11-16. A summary of such vaccines is given in Table 1. However, difficulties in the manufacture and efficacy of the toxoid based vaccines including variation in the quantity and quality of neutralizing antibodies generated suggest an opportunity for improvement. Several groups have considered the use of recombinant antigens based on the repetitive binding domains (RBD) located at the termini of both toxin A and B. X-ray structural analysis of this region in TcdA revealed that these sequences fold into repetitive solenoid-like structures 9 that have potential as vaccine candidates. This was first demonstrated in the 1990s by Lyerly, who showed that a recombinant protein encoding 33 of the 38 regions of RBD A was sufficient to protect animals against toxin A challenge 23. These fragments generated neutralizing antibodies which appeared essential in prevention of lethality in the Syrian golden hamster model of infection. Over the intervening years, several formulations of experimental vaccines have been tested using different routes of immunisation and delivery vehicles to enhance immune responses 24-25 (Table 1). More recently, groups 24,26 have revised the formulation to include toxin B, as fragments of toxin A alone failed to provide full protection. This has shown that systemic vaccination of RBDs of both toxins can prevent lethal disease.

Most of the RBD fragments used in such studies have been cloned using genomic sequences from two strains of *C. difficile*, the highly toxic strain VPI0463 or 630 from which the first annotated sequence was generated 26. While these fragments generate strong neutralizing antibodies, documented variation in the toxin B RBD may limit the potential of these antigens to completely neutralize the activity of variant toxins. Using RBD fragments of toxin A (2387–2710 nt) and toxin B (1853–2366 nt) cloned from 630, we have shown varying degrees of protection in the hamster model using 3 different strains of *C. difficile* (Fig. 1). These differences may reflect either variation in the neutralizing capacity of the antibody to divergent toxins or differences in the amount and activity of the toxins produced in vivo. In our hands and confirmed in observations by others 60-63 appears to generate less toxin over an equivalent time period than *C. difficile* strains 81 or R20291. Variation in the amount of antigen used in vaccination has been shown to influence the level of protection with animals vaccinated with a reduced formulation (50 μg per dose of RBDs from TcdA and TcdB) being more susceptible
Table 1. Summary of vaccines formulations against C. difficile described in the literature

| Toxoids preparations | Animal model/clinical study | Route of immunization | References |
|----------------------|-----------------------------|-----------------------|------------|
| Coccidiodermatitis     | Hamster                     | Parenteral (i.p., s.c.) + mucosal (i.n., i.g., r.) | 13         |
| Partially purified toxoids A and B | Healthy adults | Parenteral (i.m.) + mucosal (i.n., i.g., r.) | 12         |
| Partially purified toxoids A and B | Patients | Parenteral (i.m.) + mucosal (i.n., i.g., r.) | 45         |
| Partially purified toxoids A and B | Healthy adults | Parenteral (i.m.) + mucosal (i.n., i.g., r.) | 14         |
| Highly purified toxoids A and B | Healthy adults, elderly | Parenteral (i.m.) + mucosal (i.n., i.g., r.) | 15         |
| Recombinant toxin-based antigens | Hamster | Parenteral (i.m.) + mucosal (i.n., i.g., r.) | 47         |
| RBD-TcdA | Rabbit | DNA vaccine, i.m. | 23         |
| RBD-TcdA/B | Mouse | adenovirus vector, i.m. | 25         |
| Surface antigens | Mice, hamster, monkey | Parenteral (i.m.) | 18         |
| Crude SLP | Mice, hamster | Parenteral (i.p., i.m.) | 34         |
| FliD | Mice | Parenteral (i.n., i.g., PEG encapsulation) | 35         |
| Cwp84 | Hamster | Parenteral (i.n., i.g., PEG encapsulation) | 36         |
| Cwp84 | Hamster | Parenteral (i.p., PEG encapsulation) | 37         |

i.p. = intraperitoneal, s.c. = subcutaneous, i.n. = intranasal, i.g. = intragastric, r. = rectal, i.m. = intramuscular

Figure 1. Survival of clindamycin-treated vaccinated hamsters challenged with C. difficile (A) shows the survival of animals following vaccination with RBD-TcdA630 and RBD-TcdB630 (50 μg per dose and/or 4 vaccinations) and challenged with C. difficile 630 (closed circles), B1 (closed square), and R2029 (closed triangles). Unvaccinated controls for each strain are also included (closed diamonds). (B) shows the survival time of animals vaccinated with 4 doses of either RBD-TcdA630 and RBD-TcdB630 (open squares) or RBD-TcdA630 and TcdB-GT630 (open circle) 50 μg per dose and challenged with C. difficile B1. Unvaccinated controls for each strain are also included (open triangles). Each experiment represents a minimum of 6 animals per group. Differences in survival for animals immunized with RBD-TcdA630 and RBD-TcdB630 between (A) and (B) may reflect the impact of a lower dose of proteins given to animals challenged with C. difficile B1 in (B).
t to faal disease (Fig. 1B). This appears particularly true for the RBD from toxin B, which in general seems to be less immunogenic than the equivalent toxin A protein. Whilst high titers of antibodies to toxin A have been observed after single vaccinations, several vaccinations are required to generate even the most limited anti toxin B response.  

Identification of Alternative and Effective Neutralising Epitopes for Toxin B  
In the last decade the number and complexity of C. difficile cases have increased worldwide and while a proportion of these cases can be attributed to increased vigilance, the emergence and spread globally of a number of hypervirulent and epidemic strains has also contributed. In the UK, the progenitor of the epidemic 027 ribotype (known as R0291 or UK1) was isolated in 2006 at Stoke Mandeville during an outbreak that resulted in over 30 deaths. The spread and evolution of this strain worldwide has recently been documented, although a conclusive explanation for its rapid spread and dominance remains elusive. However, it is clear that vaccines of the future need to show efficacy against such strains. While the use of a TcdB toxoid appears to generate immunity that is cross protective between phylogenetically distinct C. difficile strains, the RBD region of this toxin has been reported to be variable between different toxinotypes. We and others have considered the use of other more conserved regions of the toxin as vaccine candidates. More specifically, we have shown that a recombinant fragment encoding the glucosyltransferase activity of toxin B (TcdB-GT 1–543 nt) in combination with the RBD region of toxin A can raise neutralizing antibodies. This fragment appears to generate superior protective responses to the equivalent RBD of toxin B when used in combination with RBD from toxin A in parallel experiments (Fig. 1B). Inclusion of this region has also been shown in the mouse model of relapsing disease to reduce recurrence of the disease. This result provides an argument for inclusion of these domains in future superior vaccines. The potential of the catalytic domain as a source of toxin B neutralizing epitopes has further been confirmed through the creation of a chimeric protein in which the RBD of toxin B was exchanged for the equivalent RBD from toxin A.  

Protection from Local or Systemic Toxic Activity  
While activity of the toxin at the mucosal barrier is well documented, the systemic impact of toxin action is less clear. Hamsters, unlike mice, appear acutely sensitive to the toxins, with animals succumbing to an acute lethal disease between 24–48 h following oral challenge. These animals do not appear to die as a consequence of dehydration attributed to diarrhea as animals that show intermediate levels of protection suffer several episodes of diarrhea followed by recovery. In contrast, naive infected animals develop diarrhea and rapidly become moribund. Data from zebrafish and more recently from gnotobiotic pigs, have highlighted the sensitivity of cardiovascular and pulmonary tissue to C. difficile toxins. While no gross pathology has been observed in these tissues in hamsters, our current use of biotelemetry has indicated a role for these toxins systemically. Animals with acute infection show a short rise in body temperature followed by a rapid and sustained reduction that is associated with organ failure (Fig. 2). In contrast, vaccinated animals show a small but sustained elevation at the same time as the naive animals before a return to normal biorhythms. This elevation in temperature may reflect the release of cytokines such as interleukin 1β (IL-1β) and interleukin 6 (IL-6), which have been shown to be released from macrophages exposed to either TcdA or TcdB. This cytokine together with IL-6 has been shown to be higher in pigs and mice with systemic CDI and may be responsible for the increase in body temperature observed. Neutralization of toxins as a consequence of vaccination may limit inflammatory cytokine release and alter the subsequent downstream effects which in the hamsters are lethal. At present, it is unclear whether systemic toxicity has a role clinically, and it will be difficult to determine given that the majority of
infections occur in elderly hospitalized patients with complicated medical histories. However, it may be speculated that these toxins contribute indirectly to organ failures in these weakened patients. These observations further support the use and development of vaccines against the toxins.

Protection from Toxin Mediated Symptoms but Not Colonization

Systemic vaccination with *C. difficile* toxoid vaccines have been shown to generate high levels of serum antibodies that appear to reduce the potential for relapse. The difficulty with this approach is the availability of strong toxin-neutralizing activity at the epithelial barrier. In systemically vaccinated and protected animals, short and self-limiting episodes of diarrhea are frequently observed. It has been suggested that this reflects damage to the gut epithelium, initiated by early toxin production, which releases toxin-neutralizing antibodies from the local vasculature of the gut. Early studies, in which mucosal vs. systemic vaccinations were compared, indicated that only the production of mucosal responses through a combination of systemic and mucosal immunization limited these symptoms. In our hands, mucosal vaccination alone with recombinant fragments of receptor binding domains elongates survival time (by approx 10 h) but does not prevent the eventual systemic impact of the toxin (data not shown). This suggests that strategies that activate both mucosal and systemic responses would be optimal for complete prevention of symptoms.

However, is prevention of symptoms sufficient? In our hands, vaccinated animals that show limited or no diarrheal symptoms continue to shed the organism at high levels in the feces for up to 3 weeks post infection (Fig. 3A). This would suggest that while vaccination prevents

![Figure 3.](image-url)
toxin mediated symptoms it is not sufficient to prevent outgrowth, sporulation, and release of the spores into the environment. As current clinical diagnosis is dependent upon detection of toxins in fecal samples, it is possible that a vaccination strategy designed to prevent clinical symptoms could lead to an underestimation of the extent of colonization in a given target population. An ideal vaccine therefore should additionally be formulated to include bacterial factors that also limit colonization. One complication of this approach is the lack of information as to which bacterial proteins contribute to epithelial adhesion and long-term persistence. Several surface exposed antigens have been proposed including SLP, Pld, and cwp84 (Table 1) [14,17]. The impact of inclusion of these antigens in vaccine formulations has been found to vary levels of colonization. A further complication may be the location and nature of the bacterial interaction with the epithelial barrier. Evidence produced by electron microscopy and immunofluorescence suggest that while aggregates of bacteria appear associated with the epithelial barrier (Fig. 3B) bacterial counts (both vegetative and spores) recovered from the cecum and colon are in significantly higher numbers than imaging of the tissue would suggest. As a consequence it is difficult to determine whether attachment to the epithelial barrier is an essential requirement for toxin production and disease sequelae. While the usefulness of anti-colonization factors in acute disease is unclear, the potential to eradicate low grade persistent infection is attractive. In our studies, animals in the acute stage of infection show high levels of sporulation with spores detectable in both the feces and directly from gut samples (approximately 90% of the organisms recovered). In contrast, 14 days post infection of vaccinated animals or animals infected with naturally toxin deficient strains of the organism, show a much lower proportion of the recovered bacteria as spores (less than 50%) (Fig. 3A). In these animals, the majority of recovered organisms are vegetative cells and this may indicate that the organism is retained and can continue to persist as a member of the normal microbiome. The ability of \textit{C. difficile} to generate biofilms in vitro[18,19] may also play a role in protection from subsequent antibiotic treatment and this could be prevented if initial colonization was limited.

Reducing Clinical Disease and Environmental Contamination

One of the most clinically challenging problems of \textit{C. difficile} infection is the treatment of patients who initially respond to first line antibiotics (vancomycin and metronidazole) but suffer a subsequent recurrence of symptoms when these drugs are withdrawn[20]. Evidence suggests that patients who suffer a relapse either as a result of reactivation of a pre-existing infection, or infection with a different strain, are more likely to suffer subsequent episodes of the disease[21]. Susceptibility to relapse does appear to correlate with long-term modification of the gut microbiota, with microbial diversity a key factor in the control of outgrowth and subsequent toxin expression and release. This is most apparent in the elderly who suffer higher incidences of infection than younger patients exposed to equivalent antibiotic treatment. Further studies within the elderly in Ireland have recently shown that hospitalized patients show a much reduced diversity compared with healthy age matched individuals living within their own homes[22]. At this stage it is not clear whether bacteriostatic products produced by members of the microbiota or modification to host proteins, including those involved in epithelial barrier integrity and immunity, play a role in controlling \textit{C. difficile} outgrowth. Combining vaccination with long-term modifications to the microbiota through the use of bacteriotherapy could serve to both limit those with disease and long-term contamination of the environment.

Conclusion and Further Questions for Development

Vaccination with recombinant fragments from toxin A and toxin B can protect hamsters against lethal challenge with \textit{C. difficile}. While the RBD of toxin A has been shown in several studies to generate strong neutralizing and protective antibodies, less is known about the most effective antigen from toxin B. We and others have proposed that fragments encoding the glucosyltransferase activity of toxin B provide a vaccine candidate that is conserved and that generates strong neutralizing activity. The combination of these two fragments generates superior protection to that observed when the RBD region of toxin B is included in the formulation. As a consequence, we propose that an optimal vaccine against \textit{C. difficile} would include this fragment. Future improvements for a vaccine formulation should also include the identification of anti-colonization factors to limit long-term survival of the organism within the host. This has implications for reduction in the rates of relapse and may help to reduce environmental contamination[23]. While vaccination of the elderly can be difficult, experience with both pneumococcal and influenza vaccines have shown this approach has value. Identification of strong vaccine candidates that have the potential, even in this current form, to eliminate or even reduce the debilitating and distressing diarrheal symptoms associated with this disease is attractive. Its use in combination with other antigens or with other therapies provides hope in the longer term for reduction of environmental contamination and source of infection in our hospitals and health care institutions.

Disclosure of Potential Conflicts of Interest

No potential conflict of interest was disclosed.
Clostridium difficile. Vaccine 2010; 28:965-9; PMID:19941990; http://dx.doi.org/10.1016/j.vaccine.2009.03.058

Sere D, Dakss I, Hui G, Bouatta M, Makhlouf A, McBride E, Tsapis N. Encapsulation of Cwp84 into pectin matrix to form a novel oral vaccine for toxigenic C. difficile. Vaccine. 2011; 29:5742-50; PMID:21463605; http://dx.doi.org/10.1016/j.vaccine.2011.04.005

Ward S, Collins D, Horgan G, et al. Comparative genome and phenotypic analysis of Clostridium difficile 637 strains suggests the lineage-1 form is more closely related to C. difficile than to other species. FEMS Microbiol Lett. 2001; 195:141-8; PMID:11434839; http://dx.doi.org/10.1111/1574-6968.01037

Hirase H, Komatsu S, Sakai T, et al. Acquisition of Clostridium difficile toxins A and B in human infants colonized with both species. J Infect Dis 2012; 205:128-33; PMID:20452717; http://dx.doi.org/10.1093/infdis/jir338

Davison JA, O'Sullivan C, Fanning S, et al. Imaging of Clostridium difficile infection with 2,3,5-triphenyltetrazolium chloride. J Med Microbiol. 2004; 53:1527-32; PMID:15083875; http://dx.doi.org/10.1099/jmm.0.42261-0

Duerden I, Nomura T, Kiyoda S, Yamamoto H, Kato S. Clostridium difficile toxins A and B induce apoptosis in epithelial cells by a Fas/FasL dependent mechanism. J Med Microbiol. 2008; 57:855-61; PMID:18624097; http://dx.doi.org/10.1099/jmm.0.41898-0

Bamford KB, et al. Emergence and global spread of the hypervirulent pathotype NAP1/BI/NAP1 encodes a hyper-variable Toxins A and B and increased production of TcdA. J Med Microbiol. 2003; 52:857-63; PMID:14561366; http://dx.doi.org/10.1099/jmm.0.42128-0

Federle KL, Wintersman SS, Lavender GA, Thomas W Jr., Nichols R, Edelman R, Bridwell M. Monohistone T cells mediate cellular immunity to Clostridium difficile toxins in vitro. Infect Immun 1996; 64:1–10; PMID:8625717
39. Daga T, Leoni R, Ng TK, Sahni ST, Adams R, Rheem SA, Scallan M, Minson DJ, Steven D, Vonderfecht M. Multiple factor modulation biofilm formation by the anaerobic pathogen *Clostridium difficile*. J Bacteriol 2013; 195:585-95; PMID:23376955; http://dx.doi.org/10.1128/JB.01898-12

40. Figueiroa J, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gesing D. Relapse versus reinfection: recurrent *Clostridium difficile* infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012; 55(Suppl 2):S104-9; PMID:22752857; http://dx.doi.org/10.1093/cid/cis357

41. Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of relapse of *Clostridium difficile* disease with BI/NAP1/027. J Clin Microbiol 2012; 50:4078-82; PMID:23052318; http://dx.doi.org/10.1128/JCM.02291-12

42. Claeysen MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Vos W, Hanney E, Marchesi JR, Dinan TG, Fitzgerald G, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):E956-61; PMID:21477156; http://dx.doi.org/10.1073/pnas.1008997107

43. Best EL, Fawley WN, Pattison P, Wilton MH. The potential for airborne dispersal of *Clostridium difficile* from symptomatic patients. Clin Infect Dis 2010; 50:1450-7; PMID:20415567; http://dx.doi.org/10.1086/652648

44. Abou-Dola S, Kotloff KL, Kyne L, Warny M, Kelly CP, Soguioiu S, Giannasca PJ, Monath TP, Kelly EC, Sougioultzis S, Giannasca PJ, et al. *Clostridium difficile* toxoid vaccine and serum immunoglobulin G antibody response in twins. A Infect Soc Infect 2013; 71:1608-10; PMID:23959488; http://dx.doi.org/10.1128/AAC.06773-13

45. Soguioiu S, Kyne L, Doudz D, Kouras J, Monath S, Pothoulakis C, Giannasca PJ, Lou CK, Warny M, Monath TP, et al. *Clostridium difficile* toxoid vaccine in recurrent *C. difficile*-associated diarrhea. Gastroenterology 2013; 144:764-70; PMID:23694411; http://dx.doi.org/10.1053/j.gastro.2013.04.006

46. Anosov NG, Brown AM, Li L, Liu N, Cole EE, Zhang J, Mahv H, Kiviniitty H. Systemic antibody response induced by a two-component *Clostridium difficile* toxoid recombinant vaccine against *C. difficile*-associated disease in hamsters. J Med Microbiol 2013; 62:184-94; PMID:23591859; http://dx.doi.org/10.1099/jmm.0.066796-0

47. Donald RG, Finn M, Kuljanin N, Johnson E, Wilko SM, Koutal C, Zhao P, Morgan S, Yongyi S, Lee PK, et al. A novel approach to generate a recombinant toxoid vaccine against *Clostridium difficile*. Microbiology 2013; 159:1294-6; PMID:23629868; http://dx.doi.org/10.1099/mic.0.066712-0